Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.87 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.72 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.72 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.72 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.72 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.72 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.72 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.72 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.72 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.72 |
| ▸ | HDAC9 | Q9UKV0 | 5/20 | 0.72 |
| ▸ | HDAC5 | Q9UQL6 | 5/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30432125 | 0.98 | MAPK1 (0.83) | MAPK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL23794423 | 0.93 | MAPK1 (0.74) | MAPK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL428355 | 0.93 | MAPK1 (1.00) | MAPK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL11756884 | 0.89 | HDAC1 (0.75) | MAPK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL7087881 | 0.89 | HDAC1 (0.75) | MAPK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL7742564 | 0.89 | MAPK1 (0.68) | MAPK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL9183154 | 0.88 | MAPK1 (0.90) | MAPK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL29036051 | 0.88 | MAPK1 (0.67) | MAPK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL10659200 | 0.86 | MAPK1 (0.86) | MAPK1HDAC1HDAC3HDAC4HDAC7 | |
| SCHEMBL5655215 | 0.86 | MAPK1 (0.86) | MAPK1HDAC1HDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | claimed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | claimed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | claimed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | claimed |
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | LE ROUX DANIELLE MARIE (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2025151884-A1 | USE OF GLYCOSAMINOGLYCAN SULFATED POLYSACCHARIDES SUCH AS SODIUM PENTOSAN POLYSULFATE IN COMBINATION WITH PERMEATION AGENTS TO TREAT ALZHEIMER'S DISEASE | PARSONS C LOWELL (US) | 2025-07-17 | — | — | WO | disclosed |
| CN-116444392-B | Polypeptide protein medicine oral absorption promoter and preparation method and application thereof | 中国药科大学 | 2024-09-27 | — | — | CN | disclosed |
| CN-116444392-A | Polypeptide protein medicine oral absorption promoter and preparation method and application thereof | 中国药科大学 | 2023-07-18 | — | — | CN | disclosed |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | PLATINUM MONTAUR LIFE SCIENCES, LLC AND AS AGENT (KY) | 2017-07-06 | — | — | US | disclosed |
| EP-3110427-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | Urigen Pharmaceuticals, Inc. (US) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127416-A1 | COMPOSITIONS OF PENTOSAN POLYSULFATE SALTS FOR ORAL ADMINISTRATION AND METHODS OF USE | URIGEN PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | WO | disclosed |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7553872-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2009-06-30 | — | — | US | disclosed |
| US-7071214-B2 | Compounds and compositions for delivering active agents | EMISPHERE TECHNOLOGIES, INC. (US) | 2006-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260077020-A1 | ORAL PEPTIDE PHARMACEUTICAL COMPOSITION THAT FACILITATES ENHANCED ORAL ABSORPTION | VIP, GIPR, SLC10A2 | MAPK1 2609/4885HDAC1 572/4885HDAC3 847/4885 |
| US-20090324540-A1 | COMPOUNDS AND COMPOSITIONS FOR DELIVERING ACTIVE AGENTS | ABCB4, ABCB7, ALPP | MAPK1 4648/4885HDAC1 888/4885HDAC3 1377/4885 |
| US-20170189443-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES AND CONDITIONS EMPLOYING ORAL ADMINISTRATION OF SODIUM PENTOSAN POLYSULFATE AND OTHER PENTOSAN POLYSULFATE SALTS | SI, SLC20A1, SLC20A2 | MAPK1 3137/4885HDAC1 1680/4885HDAC3 2064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.